The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOncimmune Regulatory News (ONC)

Share Price Information for Oncimmune (ONC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 14.70
Bid: 14.10
Ask: 16.10
Change: 0.00 (0.00%)
Spread: 2.00 (14.184%)
Open: 14.70
High: 0.00
Low: 0.00
Prev. Close: 14.70
ONC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

PUBLIC DISCLOSURE OF TRANSACTIONS BY PDMR

30 Nov 2016 17:47

RNS Number : 6216Q
Oncimmune Holdings PLC
30 November 2016
 

30 November 2016

 

Oncimmune Holdings plc

("Oncimmune" or the "Company")

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PDMR

 

Oncimmune Holdings plc (AIM: ONC.L), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® platform technology, today announces that on 30 November 2016, options over ordinary shares of 1 pence each in the capital of the Company ("Ordinary Shares") were awarded to Dan Calvo, President of Oncimmune (USA) LLC, a PDMR, as well as to certain other US staff, under the Company's Oncimmune Holdings Plc Incentive Stock Option Plan (as amended from the Oncimmune Limited Incentive Stock Option Plan that became effective 27 July 2009) as follows:

 

Name

Position

Number of share options awarded

Option exercise price per share (pence)

Interest in issued share capital (%)

Dan Calvo

President of Oncimmune (USA) LLC

10,151

118.5

0.02

 

The options are subject to the rules of the Incentive Stock Option Plan and vest in five equal annual parts, the first fifth vesting on 29 November 2017 and each year thereafter for a further four years, subject to continued employment. The options are exercisable at 118.5 pence, being the mid-market closing price of the Ordinary Shares on 29 November 2016

 

For further information:

 

Oncimmune Holdings plc

Geoffrey Hamilton-Fairley, Chief Executive Officer

contact@oncimmune.co.uk

 

Zeus Capital Limited (Nominated Adviser and Broker)

Phil Walker, Giles Balleny, Dominic Wilson

+44 (0) 203 829 5000

 

Media enquiries:

Consilium Strategic Communications

Chris Gardner, Mary-Jane Elliott, Matthew Neal, Lindsey Neville

oncimmune@consilium-comms.com

+44 (0) 20 3709 5708

 

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name 

Dan Calvo

2

Reason for the notification

a)

Position/status 

President of Oncimmune (USA) LLC

b)

Initial notification/Amendment

 

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Oncimmune Holdings plc

b)

LEI

N/A

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 Identification code

options over Ordinary Shares - Oncimmune Holdings Plc Incentive Stock Option Plan

 

ISIN GB00BYQ94H38

b)

Nature of the transaction

 

Grant of options over Ordinary Shares

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

N/A

10,151

d)

Aggregated information

 

Price(s)

Volume(s)

N/A

10,151

e)

Date of the transaction

 

30 November 2016

f)

Place of the transaction 

N/A

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHURSBRNNAAOAA
Date   Source Headline
28th Apr 20177:00 amRNSFirst Distribution Agreements Signed
24th Apr 20179:18 amRNSGRANT OF OPTIONS
3rd Apr 20177:00 amRNSAppointment of Senior VP, MA & Reimbursement
3rd Apr 20177:00 amRNSGRANT OF OPTIONS AND DEALING BY PDMR
29th Mar 20173:35 pmRNSHolding(s) in Company
10th Feb 20177:00 amRNSInterim Results
8th Feb 20177:00 amRNSNotice of Interim Results
6th Dec 20167:00 amRNSPositive interim data from NHS Screening Trial
30th Nov 20165:47 pmRNSPUBLIC DISCLOSURE OF TRANSACTIONS BY PDMR
30th Nov 201610:47 amRNSResult of Annual General Meeting
8th Nov 20166:25 pmRNSGrant of options
7th Nov 20167:00 amRNSFinal Results
24th Oct 20167:00 amRNSNotice of Full Year Results
11th Oct 20167:00 amRNSBoard Appointment
22nd Sep 20167:00 amRNSAppointment of Chief Commercial Officer Asia
20th Sep 20167:00 amRNSPublication in Journal of Thoracic Oncology
17th Aug 20167:00 amRNSAndrew Millet appointed to the Board as CFO
15th Jul 20167:00 amRNSCE Mark for EarlyCDT®-Lung
4th Jul 20167:00 amRNSResearch Agreements in Ovarian and Liver Cancer
23rd Jun 20161:47 pmRNSBoard Appointment
6th Jun 20162:15 pmRNSDeath of a Director
25th May 20167:00 amRNSOncimmune Signs Three US Distribution Agreements
20th May 20167:00 amRNSHolding(s) in Company
18th May 20167:00 amRNSFirst Day of Dealings on AIM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.